Evidence map›Paper›PMID 42049397›Full record

ArticleIn vivo (Athens, Greece)

The Role of ACE I/D Polymorphism in Glioblastoma Pathogenesis: A Study on the Turkish Population.

Okan Türk, Yahya Güvenç, Seda Güleç Yilmaz, Cumhur Kaan Yaltirik, Nail Demirel, Adnan Dağçinar, Oğuz Alp Çakir, Nafiye Şanlier, Ufuk Emre Toprak, Muhammet Teoman Kurt and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Okan TürkDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye; drokanturk@yahoo.com.
Yahya GüvençDepartment of Neurosurgery, Marmara University, Istanbul, Türkiye.
Seda Güleç YilmazDepartment of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye.
Cumhur Kaan YaltirikDepartment of Neurosurgery, Faculty of Medicine, Maltepe University, Istanbul, Türkiye.
Nail DemirelDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Adnan DağçinarDepartment of Neurosurgery, Marmara University, Istanbul, Türkiye.
Oğuz Alp ÇakirDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Nafiye ŞanlierDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Ufuk Emre ToprakDepartment of Neurology, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Muhammet Teoman KurtDepartment of Neurosurgery, İstanbul Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Turgay IsbirDepartment of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimGlioblastoma multiforme (GBM) is the most aggressive primary brain tumor, with limited survival despite standard treatments such as surgery, radiotherapy, and chemotherapy. High recurrence rates after gross total resection underline the need for identifying new therapeutic targets. Angiotensin-converting enzyme (ACE) plays a role in angiogenesis and cellular proliferation, making it a potential marker in glioblastoma pathogenesis. This study aimed to evaluate the association between ACE I/D polymorphism and glioblastoma in the Turkish population and explore its potential as a therapeutic target. PATIENTS AND

methodsThe study included 35 patients with glioblastoma and 36 healthy controls. DNA was extracted from peripheral blood samples and genotyped using TaqMan SNP Genotyping Assays. Statistical analyses were conducted using IBM SPSS Statistics (v23), with chi-square and Fisher's exact tests assessing genotype and allele distribution differences. Odds ratios (OR) and 95% confidence intervals (CI) were calculated.

resultsGenotype distribution showed no significant differences between glioblastoma and control groups (

conclusionThe D allele of the ACE I/D polymorphism contributes to glioblastoma risk, highlighting ACE as a potential therapeutic target. Further studies are needed to confirm these results and investigate the clinical utility of ACE inhibitors in glioblastoma management.

Indexed as

Brain NeoplasmsGenetic Predisposition to DiseaseGlioblastomaINDEL MutationPeptidyl-Dipeptidase APolymorphism, Single NucleotideAdultAgedAllelesCase-Control StudiesFemaleGene FrequencyGenetic Association StudiesGenotypeHumansMaleACE protein, humanPeptidyl-Dipeptidase AACE polymorphismGlioblastoma multiformetherapeutic targets

Identifiers

PMID42049397
PMCPMC13133847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.